Dabigatran treatment within 24 h of a minor stroke with no evidence of AF is feasible [25], while argatroban, which directly blocks thrombin activity without the need for the cofactor antithrombin III, consequently inhibits fibrin formation, platelet aggregation, and vascular contraction induced by thrombin [26], and has been approved in China and Japan for the management of patients with AIS. Here, SERPINC1 is linked to stroke disorder.